Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Flack

Showing results (61-70 of 157) with videos related to

Pageof 16
Sort By:
Current Hypertension Reports|September 9, 2008
Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?Samar A Nasser, Zongshan Lai, Shannon O'Connor, et al.
Critical Pathways in Cardiology|July 26, 2014
Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertensionAaron M Brody, John M Flack, Brian A Ference, et al.
Journal of Hospital Medicine|February 27, 2016
The Authors Reply, "as-needed intravenous antihypertensive therapy and blood pressure control"John M Flack, Lynette R Moser, Melissa Lipari, et al.
Journal of the American Society of Hypertension : JASH|February 11, 2012
Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertensionJohn M Flack, Anthony M Yadao, Das Purkayastha, et al.
American Journal of Hypertension|May 17, 2020
Response to "COVID-19 and ACEI/ARB: Not Associated?"Ernesto L Schiffrin, John M Flack, Sadayoshi Ito, et al.
Journal of the American College of Cardiology|March 16, 2015
Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization studyBrian A Ference, Faisal Majeed, Raju Penumetcha, et al.
The American Journal of the Medical Sciences|September 21, 2002
Primary renal disease as a cardiovascular risk factorErrol D Crook, John M Flack, Mahmoud Salem, et al.
American Journal of Hypertension|April 7, 2020
Hypertension and COVID-19Ernesto L Schiffrin, John M Flack, Sadayoshi Ito, et al.
Therapeutic Advances in Cardiovascular Disease|January 1, 2010
Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trialsCarlos M Ferrario, John M Flack, John E Strobeck, et al.
Journal of Hospital Medicine|November 13, 2015
As-needed intravenous antihypertensive therapy and blood pressure controlMelissa Lipari, Lynette R Moser, Elizabeth A Petrovitch, et al.
Pageof 16

Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Current Hypertension Reports|September 9, 2008
Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?Samar A Nasser, Zongshan Lai, Shannon O'Connor, et al.
Critical Pathways in Cardiology|July 26, 2014
Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertensionAaron M Brody, John M Flack, Brian A Ference, et al.
Journal of Hospital Medicine|February 27, 2016
The Authors Reply, "as-needed intravenous antihypertensive therapy and blood pressure control"John M Flack, Lynette R Moser, Melissa Lipari, et al.
Journal of the American Society of Hypertension : JASH|February 11, 2012
Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertensionJohn M Flack, Anthony M Yadao, Das Purkayastha, et al.
American Journal of Hypertension|May 17, 2020
Response to "COVID-19 and ACEI/ARB: Not Associated?"Ernesto L Schiffrin, John M Flack, Sadayoshi Ito, et al.
Journal of the American College of Cardiology|March 16, 2015
Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization studyBrian A Ference, Faisal Majeed, Raju Penumetcha, et al.
The American Journal of the Medical Sciences|September 21, 2002
Primary renal disease as a cardiovascular risk factorErrol D Crook, John M Flack, Mahmoud Salem, et al.
American Journal of Hypertension|April 7, 2020
Hypertension and COVID-19Ernesto L Schiffrin, John M Flack, Sadayoshi Ito, et al.
Therapeutic Advances in Cardiovascular Disease|January 1, 2010
Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trialsCarlos M Ferrario, John M Flack, John E Strobeck, et al.
Journal of Hospital Medicine|November 13, 2015
As-needed intravenous antihypertensive therapy and blood pressure controlMelissa Lipari, Lynette R Moser, Elizabeth A Petrovitch, et al.
Pageof 16